pazopanib

Type: Keyphrase
Name: pazopanib
First reported Aug 23 2014 - Updated Aug 23 2014 - 1 reports

Forum Post: RE: Pazopanib

Hi I was on Pazopanib for about a year. It was the only drug that really worked on my tumors from all the chemo I had been on . It does turn your hair totally white which is quite interesting !! I did feel fatigued whilst on the drug but generally felt ... [Published Macmillan Cancer Support - Aug 23 2014]
Entities: pazopanib, Tumor, Drugs
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

Anti–PD-1 Agent Shows Activity in Renal Cell Carcinoma

Nivolumab in Renal Cell CarcinomaTable 1: Nivolumab Monotherapy in Previously Treated Renal Cell CarcinomaThe data from the trials are encouraging, as we seek to identify new treatments for [renal cell carcinoma] patients, particularly those who show ... [Published The ASCO Post - Aug 15 2014]
First reported Aug 02 2014 - Updated Aug 02 2014 - 1 reports

Exploring the role of anti-angiogenic therapies in prostate cancer: Results from the phase 3 trial of sunitinib - Abstract

Prostate cancer is a leading cause of cancer death in men.Despite recent advances in our understanding and treatment of advanced disease, no systemic therapy is curative and new therapies are needed. Targeting angiogenesis is an attractive therapeutic ... [Published UroToday - Aug 02 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Merck Serono enters anti-PD-1 fray

Merck Serono has joined the ranks of companies developing anti-PD-L1/PD-1 antibodies, revealing that it has started a phase II trial in an aggressive form of skin cancer. The mid-stage trial of the company's candidate - called MSB0010718C - is in patients ... [Published PMLive - Jul 30 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience

We retrospectively reviewed data from nine pre-treated metastatic desmoplastic small round cell tumour (DSRCT) patients who received pazopanib.Patients and methods: Three patients received pazopanib within the EORTC phase II 62043, three in the EORTC ... [Published 7thSpace - Jul 29 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Drugs to Avoid in Patients on Tyrosine Kinase Inhibitors

With the rapid and widespread uptake of tyrosine kinase inhibitors (TKIs) in oncology over the past several years, serious drug–drug interactions are an "increasing risk," according a new report.To guarantee the safe use of TKIs, "a drugs review for each ... [Published Diabetes Care - Jul 25 2014]
First reported Jul 24 2014 - Updated Jul 25 2014 - 2 reports

Forum Post: RE: Pazopanib trials

friends who have experience of kidney cancer and friendsPazopanib trialsPosted by pink sugar on24 Jul 2014 11:36 PMHas anyone been on the Pazapanib trial to see if it will stop RCC coming back?I finished taking Pazopanib last September and my last scan ... [Published Macmillan Cancer Support - Jul 25 2014]
First reported Jul 23 2014 - Updated Jul 24 2014 - 1 reports

GSK shares sink as sales decline again

GlaxoSmithKline has posted another disappointing set of financials which show that second-quarter sales fell 13%, while core operating profit sank 25% to £1.41 billion.Group sales came in at £5.56 billion, while pharmaceutical and vaccines turnover was ... [Published Pharma Times - Jul 23 2014]
First reported Jul 14 2014 - Updated Jul 14 2014 - 2 reports

The Texas Medical Board vs. Stanislaw Burzynski, Round Infinity [Respectful Insolence]

There’s a point I feel that I have have to make briefly as I begin this post. Basically, this might look familiar, but given that I was at TAM Wednesday through Sunday, I didn’t have time to produce two separate posts, and this is important enough ... [Published ScienceBlogs : Combined Feed - Jul 14 2014]
First reported Apr 02 2014 - Updated Apr 02 2014 - 2 reports

EMA App Withdrawn for GSK Ovarian Cancer Drug

GlaxoSmithKline plc announced that it has withdrawn its application to the European Medicines Agency (EMA) for a variation to the Marketing Authorization for Votrient (pazopanib). Related Biotechnology, Pharmaceutical and Healthcare NewsOriginal Article: ... [Published BioPortfolio - Apr 02 2014]
First reported Mar 31 2014 - Updated Apr 01 2014 - 4 reports

Votrient's extended licence application ditched

GlaxoSmithKline admits it is ‘disappointed’ after abandoning its attempt to extend kidney cancer drug Votrient’s licence to take in ovarian cancer.The company has withdrawn an application to the European Medicines Agency for a variation to the marketing ... [Published BioPortfolio - Apr 01 2014]
First reported Mar 13 2014 - Updated Mar 14 2014 - 3 reports

Bladder cancer patient with rare genetic mutations shows exceptional response to everolimus

A patient with advanced bladder cancer experienced a complete response for 14 months to the drug combination everolimus and pazopanib in a phase I trial, and genomic profiling of his tumor revealed two alterations that may have caused this exceptiona ... [Published BioPortfolio - Mar 13 2014]

Quotes

"In case of a suspected interaction, and if pharmacokinetic data are not available, physicians and pharmacists should balance the available evidence, if possible, extrapolate available pharmacokinetic data for an individual patient, and monitor closely for toxic effects and response" they conclude
...On a conference call to discuss the results, Sir Andrew said: "I remain very concerned about allegations concerning our China business. The situation is complicated and difficult and while the investigation is active, there is little I can add."
The lacklustre performance led to a revised full-year forecast by GSK and a prediction that core earnings per share would be "broadly similar to 2013”, compared with a previous prediction of 4%-8%."
Original Article: NEXT ARTICLE More From BioPortfolio on "GSK Launches Sri Lanka's First Targeted Treatment For Renal Cell Cancer"

More Content

All (40) | News (32) | Reports (0) | Blogs (7) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Forum Post: RE: Pazopanib [Published Macmillan Cancer Support - Aug 23 2014]
Anti–PD-1 Agent Shows Activity in Renal Cell Ca... [Published The ASCO Post - Aug 15 2014]
Acceleron Pharma's (XLRN) CEO John Knopf on Q2 ... [Published Seeking Alpha - Aug 12 2014]
ONLINE FIRST: Somatostatin Analogue Used for Ac... [Published Oncology Times - Aug 08 2014]
OXiGENE's (OXGN) CEO David Chaplin on Q2 2014 R... [Published Seeking Alpha - Aug 06 2014]
Exploring the role of anti-angiogenic therapies... [Published UroToday - Aug 02 2014]
CT Screening for Lung Cancer an Important Life-... [Published OncLive - Aug 01 2014]
Merck Serono enters anti-PD-1 fray [Published PMLive - Jul 30 2014]
Pazopanib in advanced desmoplastic small round ... [Published 7thSpace - Jul 29 2014]
Forum Post: Dad with terminal cancer and a mum ... [Published Macmillan Cancer Support - Jul 26 2014]
Drugs to Avoid in Patients on Tyrosine Kinase I... [Published Diabetes Care - Jul 25 2014]
Nexavar fails late-stage breast cancer trial [Published PMLive - Jul 25 2014]
Forum Post: RE: Pazopanib trials [Published Macmillan Cancer Support - Jul 25 2014]
Forum Post: Pazopanib trials [Published Macmillan Cancer Support - Jul 24 2014]
GlaxoSmithKline slashes forecast as 2nd-qtr sal... [Published Pharma Letter - Jul 24 2014]
GSK shares sink as sales decline again [Published Pharma Times - Jul 23 2014]
Forum Post: RE: secondary renal cancer [Published Macmillan Cancer Support - Jul 22 2014]
Forum Post: secondary renal cancer [Published Macmillan Cancer Support - Jul 21 2014]
The Texas Medical Board vs. Stanislaw Burzynski... [Published ScienceBlogs : Combined Feed - Jul 14 2014]
The Texas Medical Board vs. Stanislaw Burzynski... [Published Science-Based Medicine - Jul 14 2014]
Old member, new name? [Published HealthBoards - Jun 05 2014]
Axium Healthcare Pharmacy joins GSK oncology ne... [Published PharmaBiz - May 10 2014]
GSK Launches Sri Lanka's First Targeted Treatme... [Published BioPortfolio - May 06 2014]
Overall Survival in Renal-Cell Carcinoma with P... [Published The New England Journal of Medicine: Hematology ... - May 01 2014]
Withdrawn application: Votrient, pazopanib, Pos... [Published Withdrawn Application - Apr 25 2014]
Kidney cancer In crossover study patients and p... [Published BioPortfolio - Apr 16 2014]
EMA App Withdrawn for GSK Ovarian Cancer Drug [Published BioPortfolio - Apr 02 2014]
Results from phase III patient preference study... [Published News from Kidney Cancer Association - Apr 02 2014]
Votrient's extended licence application ditched [Published BioPortfolio - Apr 01 2014]
GSK pulls Votrient in ovarian cancer clears way... [Published BioPortfolio - Mar 31 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
The Texas Medical Board vs. Stanislaw Burzynski... [Published ScienceBlogs : Combined Feed - Jul 14 2014]
There’s a point I feel that I have have to make briefly as I begin this post. Basically, this might look familiar, but given that I was at TAM Wednesday through Sunday, I didn’t have time to produce two separate posts, and this is important enough ...
The Texas Medical Board vs. Stanislaw Burzynski... [Published Science-Based Medicine - Jul 14 2014]
As I begin this post, I’m no a miserably crowded, hot, stinky flight winging my way home from TAM . This puts me in the perfect mood to write about my bête noire to conquer all bêtes noires, namely Stanislaw Burzynski, the Polish expat doctor who ...
Old member, new name? [Published HealthBoards - Jun 05 2014]
When I was diagnosed with follicular ThyCa back in late 2005 I posted under my first and last name but after several years of inactivity I came back and found that Admin had changed my login to my first name along with a number. After several years more ...
Overall Survival in Renal-Cell Carcinoma with P... [Published The New England Journal of Medicine: Hematology ... - May 01 2014]
To the Editor: In the August 22 issue, we reported on a phase 3 trial showing the noninferiority, with respect to progression-free survival, of pazopanib versus sunitinib as first-line treatment for clear-cell, metastatic renal-cell carcinoma, as assessed ...
Withdrawn application: Votrient, pazopanib, Pos... [Published Withdrawn Application - Apr 25 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.